Gao M, Zhao B, Yang W, Tang J, Liu Y
Department of Thoracic Surgery, First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China.
Henan Provincial Key Laboratory of Esophageal Cancer Metastasis and Translational Medicine, Weihui 453100, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2023 Nov 20;43(11):1926-1934. doi: 10.12122/j.issn.1673-4254.2023.11.13.
To investigate the mechanism mediating the inhibitory effect of chidamide on esophageal squamous cell carcinoma (ESCC) cells.
ESCC cell lines KYSE-150, KYSE-450 and KYSE-510 were treated with 5, 10, 20, or 40 μmol/L of chidamide, and the changes in cell proliferation, colony-forming capacity, cell apoptosis and cell cycle were assessed using MTT aasay, colony formation experiment and flow cytometry. Western blotting was performed to detect the expression levels of cleaved caspase-3, cleaved PARP, p21, cyclin D1, p-Akt, p-ERK1/2, γH2AX, H3K9ac, and Ki-67. In a nude mouse model bearing subcutaneous ESCC xenografts, the effects of intraperitoneal injection of 20 mg/kg chidamide for 3 days on tumor size and body weight were observed every 3 days, and Ki-67 and CD31 expressions in the tumor tissues were detected using immunohistochemistry. Tubular formation experiment was used to examine the effect of chidamide on tubular formation of human umbilical vein endothelial cells (HUVECs) .
In cultured ESCC cell lines, chidamide significantly inhibited cell proliferation and colony formation ( < 0.05), promoted cell apoptosis, and increased the percentage of G0/G1 phase cells (all < 0.01). Chidamide obviously up-regulated cleaved caspase-3, cleaved PARP, p21, γH2AX, and H3K9ac and down-regulated cyclin D1, p-Akt and p-ERK1/2, and Ki-67 in the cells ( < 0.01). In the tumor-bearing mouse models, treatment with chidamide significantly reduced the tumor volume ( < 0.05), tumor to body weight ratio ( < 0.01), and the expression levels of Ki-67 and CD31 in the tumors ( < 0.01). Chidamide also significantly inhibited tubule formation in cultured HUVECs ( < 0.05).
Chidamide inhibits proliferation, induces apoptosis and blocks cell cycle of ESCC cells possibly by inhibiting the PI3K/Akt and ERK1/2 pathways and increasing DNA damage. Chidamide also inhibits subcutaneous tumorigenesis of ESCC cells in mice by inhibiting tumor cell proliferation and angiogenesis.
探讨西达本胺对食管鳞状细胞癌(ESCC)细胞抑制作用的介导机制。
用5、10、20或40μmol/L西达本胺处理ESCC细胞系KYSE - 150、KYSE - 450和KYSE - 510,采用MTT法、集落形成实验和流式细胞术评估细胞增殖、集落形成能力、细胞凋亡和细胞周期的变化。进行蛋白质免疫印迹法检测裂解的半胱天冬酶 - 3、裂解的聚(ADP - 核糖)聚合酶、p21、细胞周期蛋白D1、磷酸化Akt、磷酸化细胞外信号调节激酶1/2、γH2AX、组蛋白H3第9位赖氨酸乙酰化(H3K9ac)和Ki - 67的表达水平。在携带皮下ESCC异种移植瘤的裸鼠模型中,每3天观察腹腔注射20mg/kg西达本胺3天对肿瘤大小和体重的影响,并用免疫组织化学法检测肿瘤组织中Ki - 67和CD31的表达。采用管腔形成实验检测西达本胺对人脐静脉内皮细胞(HUVECs)管腔形成的影响。
在培养的ESCC细胞系中,西达本胺显著抑制细胞增殖和集落形成(P<0.05),促进细胞凋亡,并增加G0/G1期细胞百分比(均P<0.01)。西达本胺明显上调细胞中裂解的半胱天冬酶 - 3、裂解的聚(ADP - 核糖)聚合酶、p21、γH2AX和H3K9ac,下调细胞周期蛋白D1、磷酸化Akt和磷酸化细胞外信号调节激酶1/2以及Ki - 67(P<0.01)。在荷瘤小鼠模型中,西达本胺治疗显著减小肿瘤体积(P<0.05)、降低肿瘤与体重比值(P<0.01),并降低肿瘤组织中Ki - 67和CD31的表达水平(P<0.01)。西达本胺还显著抑制培养的HUVECs中的小管形成(P<0.05)。
西达本胺可能通过抑制PI3K/Akt和ERK1/2通路并增加DNA损伤来抑制ESCC细胞的增殖、诱导凋亡并阻断细胞周期。西达本胺还通过抑制肿瘤细胞增殖和血管生成来抑制ESCC细胞在小鼠体内的皮下肿瘤发生。